Autism and Fragile X Syndrome

Abstract

Autistic spectrum disorders (ASDs) are characterized by impairments in language, social skills, and repetitive behaviors, often accompanied by intellectual disability. Advances in the genetics of ASDs are providing new glimpses into the underlying neurobiological mechanisms disrupted in these conditions. These glimpses on one hand reinforce the idea that synapse development and plasticity are one of the major pathways disrupted in autism, but beyond that are providing fresh molecular support to the idea of mechanistic parallels between idiopathic ASD and specific syndromic neurodevelopmental disorders like fragile X syndrome (FXS). Fragile X syndrome is already recognized as the most common identifiable genetic cause of intellectual disability and ASDs, with many overlapping phenotypic features. Fragile X syndrome is associated with a variety of cognitive, behavioral, physical, and medical problems, which are managed through supportive treatment. Recent major advances in the understanding of the underlying neurobiology in FXS have led to the discovery of agents that rescue phenotypes in the FXS mouse model, and early clinical trials of targeted treatments in humans with FXS. Thus translational strategies in FXS may be poised to serve as models for ASD and other cognitive disorders.

Keywords

fragile X syndrome - autism spectrum disorder - fragile X mental retardation protein - fragile X mental retardation 1 geneintellectual disability

• References

• 1 Baio J. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63 (2) 1-21
• 2 Kim YS, Leventhal BL, Koh Y-J , et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168 (9) 904-912
• 3 Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. Curr Opin Neurol 2013; 26 (2) 146-153
• 4 Bauman ML. Medical comorbidities in autism: challenges to diagnosis and treatment. Neurotherapeutics 2010; 7 (3) 320-327
• 5 Doshi-Velez F, Ge Y, Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics 2014; 133 (1) e54-e63
• 6 Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Economic burden of childhood autism spectrum disorders. Pediatrics 2014; 133 (3) e520-e529
• 7 Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2012; 17 (3) 290-314
• 8 Butler MG, Dasouki MJ, Zhou X-P , et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005; 42 (4) 318-321
• 9 Geschwind DH. Advances in autism. Annu Rev Med 2009; 60: 367-380
• 10 Jeste SS. The neurology of autism spectrum disorders. Curr Opin Neurol 2011; 24 (2) 132-139
• 11 Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci 2008; 31 (3) 137-145
• 12 Folstein S, Rutter M. Genetic influences and infantile autism. Nature 1977; 265 (5596) 726-728
• 13 Steffenburg S, Gillberg C, Hellgren L , et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 1989; 30 (3) 405-416
• 14 Bailey A, Le Couteur A, Gottesman I , et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25 (1) 63-77
• 15 Lichtenstein P, Carlström E, Råstam M, Gillberg C, Anckarsäter H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010; 167 (11) 1357-1363
• 16 Ronald A, Happé F, Plomin R. Genetic research into autism. Science 2006; 311 (5763) 952 , author reply 952
• 17 Hallmayer J, Cleveland S, Torres A , et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68 (11) 1095-1102
• 18 Constantino JN, Todorov A, Hilton C , et al. Autism recurrence in half siblings: strong support for genetic mechanisms of transmission in ASD. Mol Psychiatry 2013; 18 (2) 137-138
• 19 Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. The familial risk of autism. JAMA 2014; 311 (17) 1770-1777
• 20 Cohen D, Pichard N, Tordjman S , et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord 2005; 35 (1) 103-116
• 21 Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res 2011; 1380: 42-77
• 22 Wandstrat AE, Leana-Cox J, Jenkins L, Schwartz S. Molecular cytogenetic evidence for a common breakpoint in the largest inverted duplications of chromosome 15. Am J Hum Genet 1998; 62 (4) 925-936
• 23 Goizet C, Excoffier E, Taine L , et al. Case with autistic syndrome and chromosome 22q13.3 deletion detected by FISH. Am J Med Genet 2000; 96 (6) 839-844
• 24 Prasad C, Prasad AN, Chodirker BN , et al. Genetic evaluation of pervasive developmental disorders: the terminal 22q13 deletion syndrome may represent a recognizable phenotype. Clin Genet 2000; 57 (2) 103-109
• 25 Jamain S, Quach H, Betancur C , et al; Paris Autism Research International Sibpair Study. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34 (1) 27-29
• 26 Kim H-G, Kishikawa S, Higgins AW , et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008; 82 (1) 199-207
• 27 Durand CM, Betancur C, Boeckers TM , et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39 (1) 25-27
• 28 Berkel S, Marshall CR, Weiss B , et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 2010; 42 (6) 489-491
• 29 Lai CSL, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 2001; 413 (6855) 519-523
• 30 Weiss LA, Shen Y, Korn JM , et al; Autism Consortium. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358 (7) 667-675
• 31 Christian SL, Brune CW, Sudi J , et al. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. Biol Psychiatry 2008; 63 (12) 1111-1117
• 32 Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011; 70 (5) 898-907
• 33 Marshall CR, Noor A, Vincent JB , et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82 (2) 477-488
• 34 Sebat J, Lakshmi B, Malhotra D , et al. Strong association of de novo copy number mutations with autism. Science 2007; 316 (5823) 445-449
• 35 Shen Y, Dies KA, Holm IA , et al; Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125 (4) e727-e735
• 36 Sanders SJ, Ercan-Sencicek AG, Hus V , et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70 (5) 863-885
• 37 Levy D, Ronemus M, Yamrom B , et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 2011; 70 (5) 886-897
• 38 Pinto D, Pagnamenta AT, Klei L , et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466 (7304) 368-372
• 39 Glessner JT, Wang K, Cai G , et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459 (7246) 569-573
• 40 Talkowski ME, Rosenfeld JA, Blumenthal I , et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 2012; 149 (3) 525-537
• 41 Konyukh M, Delorme R, Chaste P , et al. Variations of the candidate SEZ6L2 gene on Chromosome 16p11.2 in patients with autism spectrum disorders and in human populations. PLoS ONE 2011; 6 (3) e17289
• 42 Golzio C, Willer J, Talkowski ME , et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature 2012; 485 (7398) 363-367
• 43 Girirajan S, Rosenfeld JA, Cooper GM , et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet 2010; 42 (3) 203-209
• 44 Girirajan S, Rosenfeld JA, Coe BP , et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N Engl J Med 2012; 367 (14) 1321-1331
• 45 O'Roak BJ, Vives L, Girirajan S , et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012; 485 (7397) 246-250
• 46 Sanders SJ, Murtha MT, Gupta AR , et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012; 485 (7397) 237-241
• 47 Iossifov I, Ronemus M, Levy D , et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012; 74 (2) 285-299
• 48 O'Roak BJ, Vives L, Fu W , et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012; 338 (6114) 1619-1622
• 49 Buxbaum JD, Daly MJ, Devlin B, Lehner T, Roeder K, State MW. Autism Sequencing Consortium. The autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disorders. Neuron 2012; 76 (6) 1052-1056
• 50 Chahrour MH, Yu TW, Lim ET , et al; ARRA Autism Sequencing Collaboration. Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. PLoS Genet 2012; 8 (4) e1002635
• 51 Yu TW, Chahrour MH, Coulter ME , et al. Using whole-exome sequencing to identify inherited causes of autism. Neuron 2013; 77 (2) 259-273
• 52 Lim ET, Raychaudhuri S, Sanders SJ , et al; NHLBI Exome Sequencing Project. Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. Neuron 2013; 77 (2) 235-242
• 53 Basel-Vanagaite L, Dallapiccola B, Ramirez-Solis R , et al. Deficiency for the ubiquitin ligase UBE3B in a blepharophimosis-ptosis-intellectual-disability syndrome. Am J Hum Genet 2012; 91 (6) 998-1010
• 54 Novarino G, El-Fishawy P, Kayserili H , et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 2012; 338 (6105) 394-397
• 55 Willsey AJ, Sanders SJ, Li M , et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 2013; 155 (5) 997-1007
• 56 Helsmoortel C, Vulto-van Silfhout AT, Coe BP , et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet 2014; 46 (4) 380-384
• 57 Voineagu I, Wang X, Johnston P , et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474 (7351) 380-384
• 58 Parikshak NN, Luo R, Zhang A , et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 2013; 155 (5) 1008-1021
• 59 Neale BM, Kou Y, Liu L , et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012; 485 (7397) 242-245
• 60 Uddin M, Tammimies K, Pellecchia G , et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. Nat Genet 2014; ;46(7):742–747.
• 61 Pinto D, Delaby E, Merico D , et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet 2014; 94 (5) 677-694
• 62 Luo R, Sanders SJ, Tian Y , et al. Genome-wide transcriptome profiling reveals the functional impact of rare de novo and recurrent CNVs in autism spectrum disorders. Am J Hum Genet 2012; 91 (1) 38-55
• 63 Kelleher III RJ, Geigenmüller U, Hovhannisyan H , et al. High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS ONE 2012; 7 (4) e35003
• 64 Steinberg J, Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies. Am J Hum Genet 2013; 93 (5) 825-839
• 65 Coffee B, Keith K, Albizua I , et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009; 85 (4) 503-514
• 66 Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. Clin Genet 2011; 80 (3) 214-225
• 67 Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet 2012; 159B (5) 589-597
• 68 Tassone F, Iong KP, Tong T-H , et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012; 4 (12) 100
• 69 Ladd PD, Smith LE, Rabaia NA , et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007; 16 (24) 3174-3187
• 70 Iliff AJ, Renoux AJ, Krans A, Usdin K, Sutton MA, Todd PK. Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice. Hum Mol Genet 2013; 22 (6) 1180-1192
• 71 Berry-Kravis E, Abrams L, Coffey SM , et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007; 22 (14) 2018-2030 , quiz 2140
• 72 Berry-Kravis E, Grossman AW, Crnic LS , et al. Understanding fragile X syndrome. Curr Pediatr 2002; 12: 316-324
• 73 Kidd SL, Lachiewicz A, Barbouth D , et al. Fragile X syndrome: a review of associated medical problems. J Pediatr 2014; ; In press
• 74 Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. Int J Pediatr 2012; 2012: 843016
• 75 Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10 (1) 31-41
• 76 Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010; 7 (3) 264-274
• 77 Talisa VB, Boyle L, Crafa D, Kaufmann WE. Autism and anxiety in males with fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey. Am J Med Genet A 2014; 164A (5) 1198-1203
• 78 Bailey Jr DB, Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr 2012; 33 (1) 62-69
• 79 Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord 2011; 3 (3) 193-210
• 80 Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002; 99 (11) 7746-7750
• 81 Deng P-Y, Rotman Z, Blundon JA , et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron 2013; 77 (4) 696-711
• 82 Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol 2014; 50 (4) 297-302
• 83 Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci 2006; 26 (27) 7151-7155
• 84 Bilousova TV, Dansie L, Ngo M , et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46 (2) 94-102
• 85 Henderson C, Wijetunge L, Kinoshita MN , et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012; 4 (152) 152ra128
• 86 Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 2010; 79 (4) 632-646
• 87 McBride SMJ, Choi CH, Wang Y , et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005; 45 (5) 753-764
• 88 Michalon A, Sidorov M, Ballard TM , et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012; 74 (1) 49-56
• 89 Berry-Kravis E, Sumis A, Hervey C , et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008; 29 (4) 293-302
• 90 Leigh MJS, Nguyen DV, Mu Y , et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013; 34 (3) 147-155
• 91 Berry-Kravis EM, Hessl D, Rathmell B , et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012; 4 )152):152 ra127
• 92 Erickson CA, Wink LK, Ray B , et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013; 228 (1) 75-84
• 93 Berry-Kravis E, Hessl D, Coffey S , et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009; 46 (4) 266-271
• 94 Jacquemont S, Curie A, des Portes V , et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011; 3 (64) 64ra1
• 95 Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome Measures Working Groups. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 2013; 34 (7) 508-522
• 96 Waltes R, Duketis E, Knapp M , et al. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet 2014; 133 (6) 781-792